Center for Innovations in Medicine, Arizona State University, Tempe, Arizona, United States of America.
PLoS One. 2010 May 19;5(5):e10728. doi: 10.1371/journal.pone.0010728.
There is a pressing need for high-affinity protein binding ligands for all proteins in the human and other proteomes. Numerous groups are working to develop protein binding ligands but most approaches develop ligands using the same strategy in which a large library of structured ligands is screened against a protein target to identify a high-affinity ligand for the target. While this methodology generates high-affinity ligands for the target, it is generally an iterative process that can be difficult to adapt for the generation of ligands for large numbers of proteins.
METHODOLOGY/PRINCIPAL FINDINGS: We have developed a class of peptide-based protein ligands, called synbodies, which allow this process to be run backwards--i.e. make a synbody and then screen it against a library of proteins to discover the target. By screening a synbody against an array of 8,000 human proteins, we can identify which protein in the library binds the synbody with high affinity. We used this method to develop a high-affinity synbody that specifically binds AKT1 with a K(d)<5 nM. It was found that the peptides that compose the synbody bind AKT1 with low micromolar affinity, implying that the affinity and specificity is a product of the bivalent interaction of the synbody with AKT1. We developed a synbody for another protein, ABL1 using the same method.
CONCLUSIONS/SIGNIFICANCE: This method delivered a high-affinity ligand for a target protein in a single discovery step. This is in contrast to other techniques that require subsequent rounds of mutational improvement to yield nanomolar ligands. As this technique is easily scalable, we believe that it could be possible to develop ligands to all the proteins in any proteome using this approach.
目前迫切需要能够与人类和其他蛋白质组中所有蛋白质高亲和力结合的配体。许多研究团队都在致力于开发蛋白质结合配体,但大多数方法都是采用相同的策略,即用大量结构配体库筛选蛋白质靶标,以鉴定针对该靶标的高亲和力配体。虽然这种方法可以生成针对靶标的高亲和力配体,但它通常是一个迭代过程,难以适应大量蛋白质配体的生成。
方法/主要发现:我们开发了一类基于肽的蛋白质配体,称为 synbody,它可以使这个过程反向运行——即先构建 synbody,然后用它来筛选蛋白质文库,以发现靶标。通过将 synbody 与 8000 个人类蛋白质阵列进行筛选,我们可以确定文库中哪一种蛋白质与 synbody 具有高亲和力结合。我们使用这种方法开发了一种高亲和力的 synbody,它可以特异性地与 AKT1 结合,Kd 值<5 nM。结果发现,构成 synbody 的肽与 AKT1 的结合亲和力为低微摩尔级,这表明亲和力和特异性是 synbody 与 AKT1 二价相互作用的产物。我们使用相同的方法为另一种蛋白质 ABL1 开发了一个 synbody。
结论/意义:该方法在单个发现步骤中提供了针对靶标蛋白的高亲和力配体。这与需要随后进行多轮突变改进才能产生纳摩尔级配体的其他技术形成对比。由于这种技术易于扩展,我们相信,使用这种方法有可能为任何蛋白质组中的所有蛋白质开发配体。